Cytokinetics Announces Eleven Abstracts to be Presented at the 44th annual American Society of Cell Biology Meeting
South San Francisco, CA - November 30, 2004
Cytokinetics, Inc. (Nasdaq: CYTK) announced today that eleven abstracts relating to its research programs will be presented at the 44th Annual American Society of Cell Biology (ASCB) meeting in Washington DC. Details regarding the scientific presentations are provided below:
Sunday, December 5, 12:00 - 3:00 pm
1. Abstract #174: Activation of Cardiac Sarcomere ATPase by CK-1122534, a Small Molecule Agent that Specifically Targets Cardiac Myosin (Session 117, Muscle and Muscle-Associated Proteins I)
2. Abstract #198: Structure of Human Kip3d - Unconventional Microtubule Depolymerizing Kinesin (Session 118, Kinesin I)
3. Abstract #199: Regulation of ATPase Activity of Internal Motor Kinesin, pKinI: Binding to Microtubule Lattice is Non-productive (Session 118, Kinesin I)
Tuesday, December 7, 12:00 - 3:00 pm
1. Abstract #1480: Identification and Characterization of Candida Albicans Formins (Session 316, Actin Dynamics and Assembly II)
2. Abstract #1489: Regulation of WASP and N-WASP by Different Activators (Session 316, Actin Dynamics and Assembly II)
3. Abstract #1498: Interaction of Myosin with Blebbistatin Reported by Fluorescence Spectroscopy (Session 317, Conventional Myosin)
4. Abstract #1499: The Cardiac Myosin Activator, CK-1122534, Overcomes the Myosin II Inhibitors 2, 3-Butanedione-2-Monoxime and (-)-S-Blebbistatin without Affecting the Ca2+ Transient in Ventricular Myocytes (Session 317, Conventional Myosin)
5. Abstract #1500: The Cardiac Myosin Activator, CK-1122534, Increases Contractility in Adult Cardiac Myocytes without Altering the Calcium Transient (Session 317, Conventional Myosin)
6. Abstract #1501: Cellular Responses of the Myosin Activator CK-0689705 in Normal and Heart Failure Models (Session 317, Conventional Myosin)
Wednesday, December 8, 12:00 - 3:00 pm
1. Abstract #2128: Vasodilator-Stimulated Phosphoprotein (VASP) Promotes Arp2/3 Complex Mediated Actin Polymerization, Prevents Branching and Stabilizes Actin Filaments (Session 416, Actin Dynamics and Assembly III)
2. Abstract #2191: A High Throughput Screen for Inhibitors of Microtubule Depolymerizing Enzyme from Plasmodium Falciparum (Session 419, Microtubule Dynamics and Assembly II)
About Cytokinetics
Cytokinetics is a leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics' focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease, fungal diseases and other diseases. Cytokinetics has developed a cell biology driven approach and proprietary technologies to evaluate the function of many interacting proteins in the complex environment of the intact human cell. Cytokinetics employs the PUMA™ system and Cytometrix™ technologies to enable early identification and automated prioritization of compounds that are highly selective for their intended protein targets without other cellular effects, and are thereby less likely to give rise to clinical side effects. Cytokinetics and GlaxoSmithKline have entered into a strategic alliance to discover, develop and commercialize small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. GlaxoSmithKline is conducting Phase II and Phase Ib clinical trials for SB-715992 and a Phase I clinical trial for SB-743921, each a drug candidate that has emerged from the strategic alliance. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to the expected timing, scope and results of our clinical development and research programs and statements regarding the potential benefits of our drug candidates and potential drug candidates and the enabling capabilities of our proprietary technologies. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of Cytokinetics' drug candidates that could slow or prevent clinical development, product approval or market acceptance (including the risks related to uncertainty of patent protection for Cytokinetics' intellectual property or trade secrets, Cytokinetics' ability to obtain additional financing if necessary and unanticipated research and development and other costs). For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
